Longboard Pharmaceuticals, Inc. (LBPH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4275 Executive Square
La Jolla, CA 92037
United States of America (the)
Phone
619 592 9775
Sector
Healthcare
Industry
Biotechnology
Employees
50
First IPO Date
March 12, 2021
| Name | Title | Pay | Year Born |
| Kevin R. Lind | President, Chief Executive Officer, Secretary & Director | 1.07M | 1976 |
| Brandi L. Roberts | Executive Vice President & Chief Financial Officer | 662,653 | 1974 |
| Randall E. Kaye | Executive Vice President & Chief Medical Officer | 717,954 | 1962 |
| Anne Danks | Vice President & Head of Nonclinical Research & Development | 0 | N/A |
| Dewey McLin | Vice President & Head of Medical Affairs | 0 | N/A |
| Marco Peters | Vice President & Head of Translational Science | 0 | N/A |
| Chadwick J. Orevillo | Executive Vice President & Head of Operations | 0 | N/A |
| Gus Cardenas | Vice President & Head of Quality Assurance | 0 | N/A |
| Steven W. Spector | Executive Vice President, Head of Business Development & General Counsel | 0 | 1965 |
| Megan E. Knight | Vice President & Head of Investor Relations | 0 | N/A |
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.